1 citations
,
October 2025 in “International Journal of Molecular Sciences” Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
2 citations
,
November 2024 in “In Silico Pharmacology” 1 citations
,
May 2021 in “Clinical Nuclear Medicine” Platelet-rich plasma therapy can increase FDG uptake in the scalp.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
3 citations
,
November 2022 in “Advances in Clinical and Experimental Medicine” Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.
7 citations
,
January 2017 in “International Journal of Trichology” Chemotherapy and certain hair care practices can cause severe hair matting.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
11 citations
,
May 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Identical p53 gene mutations in different cancers suggest the need for careful treatment.
5 citations
,
January 2021 in “Indian Journal of Pharmacology” Nilotinib can cause generalized keratosis pilaris.
19 citations
,
September 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.
3 citations
,
February 2018 in “Vigilância Sanitária em Debate” Platelets and their derivatives, like PRP, can help tissue regeneration, but need standardized safety protocols.
November 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” 4-aminopyridine helps skin wounds heal faster and better.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
1 citations
,
October 2019 in “Epileptic disorders” A girl with Pitt-Hopkins syndrome developed curly hair as a rare side effect from the epilepsy drug perampanel.
May 2018 in “Dermatologic Surgery” 34 citations
,
January 2022 in “Human Reproduction Open” PRP injections did not significantly improve ovarian function in women with low ovarian reserve.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
26 citations
,
November 2016 in “European Journal of Clinical Pharmacology” Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.